Shots:

• The P-III SAVE-MORE study involves assessing the efficacy and safety of anakinra (100mg/day- SC for up to 10 days) + SoC guided by suPAR vs PB0 + SOC in 600 hospitalized patients in mod. to sev. COVID-19 pneumonia over 28days across 40 sites in Greece and Italy
• The study demonstrated improvement in the overall clinical outcomes by 64% @28 days as measured by the ordinal scale of the 11-point CPS- reduction in either death or progression to severe respiratory failure and increase the no. of patients who were discharged from hospital with no evidence of COVID-19 infection
• Sobi plans to discuss the results with regulatory authorities to evaluate the possibility of approval

  Ref: Sobi | Image: Sobi